



O I P E  
JAN 08 2002  
JC184  
PATENT & TRADEMARK OFFICE  
UNITED STATES

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/917,376	07/28/2001	Shi-You Ding	NREL 01-36

23712  
PAUL J WHITE, SENIOR COUNSEL  
NATIONAL RENEWABLE ENERGY LABORATORY (NREL)  
1617 COLE BOULEVARD  
GOLDEN, CO 80401-3393

CONFIRMATION NO. 9956  
FORMALITIES LETTER



\*OC00000006511240\*

Date Mailed: 09/04/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

RECEIVED  
JAN 15 2002  
TECH CENTER 1600/2900

*A copy of this notice **MUST** be returned with the reply.*

~~Customer Service Center~~

Initial Patent Examination Division (703) 308-1202

PART 3 - OFFICE COPY



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Shi-You Ding et al. )  
Serial No.: 09/917,376 ) Art Unit: 1633  
Filing Date: July 28, 2001 ) Examiner: Not Yet Accorded  
Title: Thermal Tolerant Avicelase from ) Atty. Dkt. No.: NREL 01-36  
*Acidothermus cellulolyticus* )

JAN 15 2002  
ER 1600/2900

RECEIVED

**CERTIFICATE OF MAILING UNDER 37 CFR § 1.8**

I hereby certify that the following attached items:

- (1) Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure - Part 3 [2 pages]
- (2) Statement for Support Filing and Submission in Accordance with 37 CFR §§ 1.821-1.825 [2 pages]
- (3) Sequence Listing [14 pages]
- (4) Copy Computer Readable Disk
- (5) Postcard receipt

are being deposited in the United States Postal Service as first class mail, postage pre-paid, in an envelope addressed to: Assistant Commissioner for Patents, Customer Service Center, Initial Patent Examination Division, Washington, DC. 20231 on this 30th day of October 2001.

Brenda E. Brantley  
Patent Administrator

National Renewable Energy Laboratory  
1617 Cole Boulevard  
Golden, CO 80401  
303/384-7572  
303/384-4799 (fax)